First case of a renal cyst infection caused by *Desulfovibrio*: a case report and literature review

Yoshiki Okamoto¹, Yoei Miyabe¹*, Momoko Seki¹, Yusuke Ushio¹, Keisuke Sato¹, Eri Kasama¹, Kenichi Akiyama¹, Kazunori Karasawa¹, Keiko Uchida¹, Ken Kikuchi², Kosaku Nitta¹, Takahito Moriyama¹ and Junichi Hoshino¹

**Abstract**

**Background:** Genus *Desulfovibrio* species is a sulphate-reducing anaerobic gram-negative rod that resides in the human oral cavity and intestinal tract. It was reported as the causative pathogen of bacteraemia and abdominal infections, but not renal cyst infection, and *Desulfovibrio fairfieldensis* has higher pathogenicity than other *Desulfovibrio* species.

**Case presentation:** A 63-year-old man was on haemodialysis for end-stage renal failure due to autosomal dominant polycystic kidney disease. On admission, he had a persistent high-grade fever, right lumbar back pain, and elevated C-reactive protein levels. His blood and urine cultures were negative. He received ciprofloxacin and meropenem; however, there was no clinical improvement. Contrast-enhanced computed tomography and plain magnetic resonance imaging revealed a haemorrhagic cyst at the upper pole of the right kidney. The lesion was drained. Although the drainage fluid culture was negative, *D. fairfieldensis* was detected in a renal cyst using a polymerase chain reaction. After the renal cyst drainage, he was treated with oral metronidazole and improved without any relapse.

**Conclusions:** To the best of our knowledge, this is the first reported case of a renal cyst infection with *Desulfovibrio* species. *D. fairfieldensis* is difficult to detect, and polymerase chain reaction tests can detect this bacterium and ensure better management for a successful recovery.

**Keywords:** *Desulfovibrio* species, *Desulfovibrio fairfieldensis*, Renal cyst infection, Haemodialysis, Case report

**Background**

Genus *Desulfovibrio* is an anaerobic gram-negative rod and a type of sulphate-reducing bacteria belonging to more than 30 species residing in the human oral cavity, intestinal tract, and nature, including soil, sewage, and brackish water [1]. *Desulfovibrio fairfieldensis* has higher pathogenicity and more antimicrobial resistance than other *Desulfovibrio* species [1–4]. It may be the causative pathogen of bacteraemia and abdominal infections, such as abscesses and cholecystitis [1]. There are several reports of infections such as brain abscesses, meningitis, intra-abdominal abscesses, and bacteraemia caused by *Desulfovibrio* species [1–3, 5–7], but not renal cyst infection. Here, we report a case of renal cyst infection caused by *D. fairfieldensis*; this is the first such report.
Case presentation

A 63-year-old man, who was a glass craftsman and a sewer cleaner, on haemodialysis for 19 years due to autosomal dominant polycystic kidney disease (ADPKD), was referred by his family doctor for suspicion of renal cyst infection after presenting with a persistent fever of approximately 38°C, right lumbar back pain, and elevated C-reactive protein (CRP) levels for the past 14 days. Although he had received intravenous ceftriaxone for two days and meropenem and levofloxacin for 12 days, he displayed no clinical improvement. On admission, he had a fever of 38.4°C and negative blood and urine cultures (Fig. 1a). His blood tests revealed leucocytosis (9280/μL), thrombocytopenia (77000/μL), elevated CRP levels (11.09 mg/dL), and elevated procalcitonin levels (0.94 ng/mL). Plain computed tomography (CT) revealed a right renal cyst infection. Although treatment with intravenous ciprofloxacin (0.4 g/day) had been started, his clinical findings did not improve. Therefore, his treatment was changed to meropenem (0.5 g/day) on Day 9 to cover extended-spectrum β-lactamase-producing bacteria since meropenem had been reported to provide poor penetration into infected cysts but clinical improvement [8]. Contrast-enhanced CT and plain magnetic resonance imaging (MRI) were also performed (Fig. 1b). They revealed a haemorrhagic cyst at the upper pole of the right kidney, which was suspected to be the cause of the infection; percutaneous drainage of the renal cyst was performed on Day 13, and 200 mL of fluid was drained. The subsequent drainage volume was approximately 20 mL daily for 1 week. After drainage, the patient’s body temperature reduced to approximately 36.7°C. In addition, the leucocytosis, thrombocytopenia, elevated CRP, and procalcitonin levels were resolved. The drainage fluid culture was negative for bacteria, including anaerobes and fungi. Therefore, a polymerase chain reaction (PCR) test of 16S rDNA using 27FN (AGA GTT TGATCMTGG CTC AG) and 1525R (AAAGGAGGTAGTCAGCC) primers was performed for purified DNA from the drainage fluid. On Day 30, it turned out that the obtained sequences were 99.7% identical (1500/1505 bp) to that of *D. fairfieldensis* ATCC 700045T (U42221). Therefore, on Day 31, his treatment was changed to oral metronidazole (1 g/day). The volume of drained fluid decreased to 0–2 mL on Day 34, and contrast-enhanced CT performed on Day 35 showed shrinkage of the renal cysts. His clinical findings normalised, and the drainage tube was removed on Day 36. The Japanese guidelines for treating renal cyst infection in patients with ADPKD recommend a treatment period of at least 4 weeks with antimicrobial agents [9]. Therefore, on Day 38, he was discharged and asked to continue oral metronidazole for 4 weeks. After that, there was no relapse of the infection.

Discussion and conclusions

Genus *Desulfovibrio* was first described in 1895 [10], and a human infection (bacteraemia associated with cholecystitis) with *D. desulfuricans* was first reported in 1987 [11]. However, it was later considered to be *D. fairfieldensis* in 2005 because the strain was positive for catalase and nitrate. Optical and electron micrographs of *D. fairfieldensis* were published in 1996 and 1997 [6, 12], and the first human infection with *D. fairfieldensis* was reported in Fairfield, Australia; it presented as a liver abscess [6]. Subsequently, we searched PubMed and Google scholar and reported human cases of infection with *Desulfovibrio* species, including *D. desulfuricans*, *D. fairfieldensis*, *D. piger*, and *D. legallii*, were found in 26 articles (Table 1). *D. fairfieldensis* has been isolated from several sites of infection, including blood [2–4, 7, 12], peritoneal fluid [4], periodontal pockets [29, 30], the pelvis and colon [4], liver abscesses [6], and urine [5]. This report describes the first case of renal cyst infection caused by the genus *Desulfovibrio*. When our case is added to those previously reported, *D. fairfieldensis* infection is the most common (26 cases, 36%), followed by *D. desulfuricans* (24 cases, 33%), with bacteraemia and intra-abdominal infection being the commonest presentations (Table 2).

Because renal cyst infections in patients with ADPKD are frequent and refractory and patients on haemodialysis are immunocompromised [31], identification and eradication of the causative organism are essential [32]. The causative organisms of renal cyst infections have only been identified in 49% of cases, and the most common causative organisms are gram-negative rods from the intestinal tract [32, 33]. Therefore, the actual infection rate by *Desulfovibrio* species may be underestimated because of the difficulty in identifying anaerobic bacteria [3, 17] and the actual number of infections by anaerobic bacteria, including *Desulfovibrio* species, maybe much higher. No strain was cultured in this patient’s blood, urine, or renal cyst fluid, but *D. fairfieldensis* was detected in the renal cyst fluid by PCR testing. PCR is useful in identifying organisms that cannot be grown in vitro or in cases where existing culture techniques are not sensitive enough and/or require long incubation times due to its tremendous sensitivity, specificity, and amplification speed [34]. In previous reports, PCR tests using 16S rDNA were used to identify 87% of *Desulfovibrio* species, while biochemical methods were used in 13% (Table 2). Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) was also used in only 5.6% of the cases (Table 2); however, its use for
Fig. 1  
(a) Chart of patient’s clinical course after admission. The lower graph shows the patient’s body temperature, white blood cell count, and C-reactive protein levels during hospitalisation. Renal cyst drainage was performed on Day 13, and the fluid drained initially was 200 mL. A PCR test performed on Day 30 revealed that the causative bacteria was *Desulfovibrio fairfieldensis*. The middle graph shows the volume of fluid drained. The drained fluid volume could not be measured for two days after the initial drainage. The upper bar shows the antibacterial drug administered, the dose, and the timing of switching; BT, body temperature; CIP, ciprofloxacin; CRP, C-reactive protein; MEM, meropenem; MNZ, oral metronidazole; PCR, polymerase chain reaction; WBC, white blood cell count.  
(b) Diffusion-weighted imaging of plain abdominal magnetic resonance imaging (MRI) on Day 9 of admission. White arrow: a renal haemorrhagic cyst.
| Case no. | Age (yrs) | Sex | Infection | Source | Genus/species | Co-isolated/co-infected organism(s) | Identification | Time for positive incubation | Antibiotic susceptibility (Susceptible) | Antibiotic therapy | Outcome | Ref. |
|---------|-----------|-----|-----------|--------|--------------|-----------------------------------|---------------|-----------------------------|--------------------------------------|-----------------|---------|------|
| 1       | 39        | M   | Sinusitis, gingivitis, brain abscess | Pus    | D. desulfuricans | Streptococcus constellatus, Capnocytophaga ochracea, Cubicterium exiguum | Biochemical   | 10 days                   | AMC, IPM, MNZ | CTX, FOE, ONZ, PIP, PEF | Survived | [3, 13] |
| 2       | 3         | F   | Appendix abscess | Pus    | D. desulfuricans | B. mephae, E. lentum, E. coli, Enterococcus sp. | 16S rDNA | unknown | unknown | unknown | unknown | Survived | [3] |
| 3       | 61        | F   | Abdominal wall abscess, peritonitis | Pus    | D. desulfuricans | B. fragilis, E. lentum, Clostridium sp, E. coli, Enterobacter cloacae, Enterococcus sp. | 16S rDNA | unknown | unknown | unknown | unknown | Survived |
| 4       | 80        | M   | Peritonitis | Peritoneal fluid | D. desulfuricans | E. coli, Enterobacter cloacae | 16S rDNA | unknown | unknown | unknown | unknown | unknown | [14] |
| 5       | 64        | M   | Bacteraemia | Blood | D. desulfuricans | None | 16S rDNA | 6 days | unknown | unknown | LVX, MXF, GAT, MNZ, CLI, IPM, ETP, DOX | Survived | [1] |
| 6–8     | unknown   | unknown | Bacteraemia, sacral decubitus ulcer | Blood | D. desulfuricans | unknown | 16S rDNA | unknown | unknown | unknown | AMX, AMC, CLI, IPM, MNZ | Survived | [4] |
| 9       | 86        | F   | Bacteraemia, ulcerative colitis | Blood | D. desulfuricans | E. lenta | 16S rDNA | 5 days | unknown | unknown | CXM, AMX | unknown | [15] |
| 10      | 60        | M   | Bacteraemia | Blood | D. desulfuricans | None | 16S rDNA | 8 days | unknown | unknown | CLI, MNZ, ERY, AMC, MEM | Survived | [16] |
| 11      | 69        | F   | Bacteraemia, ulcerative colitis | Blood | D. desulfuricans | Cytoomegalovirus | 16S rDNA | 7 days | unknown | unknown | CLI, MNZ, ERY, AMC, MEM | Survived | [17] |
| 12      | 87        | M   | Bacteraemia, colitis | Blood | D. desulfuricans | None | 16S rDNA | 12 days | unknown | unknown | SAM, TZP, AMC, FEP, MEM | Survived | [18] |
| 13      | 69        | M   | Bacteraemia | Blood | D. desulfuricans | None | 16S rDNA | 5 days | unknown | unknown | IPM, MNZ | OFX, TZP | Survived | [19] |
| Case no. | Age (yrs) | Sex | Infection | Source | Genus/species | Co-isolated/co-infected organism(s) | Identification | Time for positive incubation | Antibiotic susceptibility (Susceptible) | Antibiotic therapy | Outcome | Ref. |
|----------|-----------|-----|-----------|--------|--------------|------------------------------------|---------------|-------------------------------|------------------------------------------|------------------|---------|------|
| 14       | 66        | F   | Hydronephrosis, suspected colon-ureteral/vesical fistula | Urine from percutaneous nephrostomy | *D. desulfuricans* | Anaerobic Gram-positive bacilli, anaerobic Gram-positive cocci, *Streptococcus agalactiae*, *Actinobaculum schaalii*, *Propionimicrobium* spp. | 16S rDNA | unknown | CLI, MNZ, PEN | unknown | Died, secondary to herpes encephalitis | [20] |
| 15       | 76        | M   | Bacteraemia, diverticulitis | Blood | *D. desulfuricans* | None | 16S rDNA | 3 days | MNZ | unknown | Survived | | |
| 16       | 60        | M   | Colonic rupture | Spine tissue | *D. desulfuricans* | *Mobiluncus curtisi*, *Candida albicans*, *Clostridium clostridiiforme* | 16S rDNA | unknown | CLI, MNZ, PEN | unknown | Died | | |
| 17       | 74        | F   | Bacteraemia, small-bowel obstruction | Blood | *D. desulfuricans* | None | 16S rDNA | 3 days | CLI, MNZ, TZP, ETP | unknown | Survived | | |
| 18       | 57        | M   | Perforated acute appendicitis | Blood | *D. desulfuricans* | In peritoneal fluid: *E. coli*, *K. pneumoniae*, anaerobic Gram-negative and -positive rods | 16S rDNA | 4 days | CLI, MNZ, SAM, ETP | unknown | Survived | | |
| 19       | 82        | M   | Bacteraemia, liver abscess | Blood | *D. desulfuricans* | None | Biochemical, 16S rDNA | 15 days | AMP, AMC, IPM, PAPM, CLI, LVX | CMZ, TZP, AMC | Survived | [21] |
| 20       | 73        | F   | Sepsis, liver abscess | Blood, pus | *D. desulfuricans* | *E. coli* | 16S rDNA | 3 days | LVX, MEM, SAM | MEM, SBT/CPZ, SAM, SBTPC | Survived | [22] |
| 21       | 88        | M   | Bacteraemia, mediastinal abscess | Blood | *D. desulfuricans* | None | 16S rDNA | 3 days | unknown | unknown | Survived | [10] |
| 22       | 53        | M   | Bacteraemia | Blood | *D. desulfuricans* | None | MALDI-TOF MS | 3 days | MNZ, AMC, IPM, CLI | AMC, TZP | Survived | [23] |
| 23       | 53        | F   | Trochanteric arthritis | Synovial fluid | *D. desulfuricans* | None | MALDI-TOF MS | 6 days | MNZ, AMC | FEP, VAN, CRO, MNZ | Survived | [24] |
| 24       | 67        | M   | Cholecystitis | Blood | *D. fairfieldensis*(*) | None | Biochemical | unknown | PEN, CLI, CHL, TET, ERY | None | Survived | [11] |
| Case no. | Age (yrs) | Sex | Infection | Source          | Genus/species | Co-isolated/ co-infected organism(s) | Identification | Time for positive incubation | Antibiotic susceptibility (Susceptible) | Antibiotic therapy | Outcome | Ref.   |
|----------|-----------|-----|-----------|-----------------|---------------|-------------------------------------|----------------|-------------------------------|------------------------------------------|-------------------|----------|--------|
| 25       | 82        | M   | Liver abscess | Pus             | *D. fairfieldensis* | *Fusobacterium varium* | 16S rDNA | 7 days                      | MNZ                        | CTX, MNZ, AMP, CIP | Survived | [6]    |
| 26       | 75        | M   | Bleeding colonic polyps | Blood | *D. fairfieldensis* | None                                | 16S rDNA | 6 days                      | MNZ, CHL, CIP, IPM, AMC, TIM, AZM, CLI | LEX, CIP         | Survived | [12]   |
| 27       | 46        | F   | Meningoencephalitis | Urine         | *D. fairfieldensis* | None                                | 16S rDNA | 14 days                     | IPM, CIP, RIF, CLI, MNZ, CHL | AMP, RIF, EMB, INH, ACV, anti-mycobacterial drugs | Died    | [5]    |
| 28       | 23        | M   | Perforating appendicitis, peritonitis | Blood       | *D. fairfieldensis* | None                                | Biochemical, 16S rDNA | 5 days                      | MNZ, IPM, CLI | FAM, MNZ         | Survived | [3]    |
| 29       | 59        | F   | Intra-abdominal abscess | Pus           | *D. fairfieldensis* | *B. vulgatus, E. lentum, E. coli, K. pneumoniae, Streptococcus intermedius* | 16S rDNA | unknown                    | MNZ, CLI                  | unknown          | Survived |        |
| 30       | 85        | M   | Abdominal abscess | Blood         | *D. fairfieldensis* | *B. fragilis, B. uniformis, B. vulgatus, B. thetaotaomicron, Clostridium innocuum, Clostridium sp., Enterococcus avium* | 16S rDNA | unknown                    | MNZ, CLI                  | unknown          | Survived |        |
| 31       | 65        | M   | Abdominal wall abscess | Pus           | *D. fairfieldensis* | *B. thetaotaomicron, E. lentum, E. coli, K. pneumoniae, Proteus vulgaris, Enterococcus sp., Streptococcus intermedius* | 16S rDNA | unknown                    | MNZ, CLI                  | unknown          | Survived |        |
| 32       | 32        | M   | Appendicitis, peritonitis | Peritoneal fluid | *D. fairfieldensis* | unknown                                | 16S rDNA | unknown                    | unknown                  | unknown          | unknown | unknown |
| 33       | 29        | F   | Appendicitis, peritonitis | Peritoneal fluid | *D. fairfieldensis* | unknown                                | 16S rDNA | unknown                    | unknown                  | unknown          | unknown | unknown |
| 34       | 53        | F   | Peritonitis | Peritoneal fluid | *D. fairfieldensis* | unknown                                | 16S rDNA | unknown                    | unknown                  | unknown          | unknown | unknown |
| 35       | 21        | M   | Appendicitis | Intra-abdominal collection | *D. fairfieldensis* | unknown                                | 16S rDNA | unknown                    | unknown                  | unknown          | unknown | unknown |
Table 1 (continued)

| Case no. | Age (yrs) | Sex | Infection | Source | Genus/species | Co-isolated/ co-infected organism(s) | Identification | Time for positive incubation | Antibiotic susceptibility (Susceptible) | Antibiotic therapy | Outcome | Ref. |
|----------|-----------|-----|-----------|--------|---------------|-------------------------------------|----------------|-------------------------------|--------------------------------------|------------------|---------|------|
| 36–45    | unknown   | unknown | unknown   | unknown | D. fairfieldensis | None | 16S rDNA | 4 days | unknown | unknown | unknown | unknown | unknown | unknown | unknown | [4] |
| 46       | 77        | M    | Afterchoanal- | Blood | D. fairfieldensis | E. coli, Morganella morganii | 16S rDNA | 9 days | MNZ, CLI, IPM, BIPM, DOR | BIPM, CFZ | Survived | [2] |
| 47       | 69        | F    | Bacteraemia | Blood | D. fairfieldensis | Parvimonas micra | MALDI-TOF MS, 16S rDNA | 7 days | None | None | None | Survived | [7] |
| 48       | 69        | F    | Bacteraemia, | Blood | D. fairfieldensis | Parvimonas micra | MALDI-TOF MS, 16S rDNA | 7 days | None | None | None | Survived | [25] |
| 49       | 63        | M    | Renal cyst infection | Pus | D. fairfieldensis | None | 16S rDNA | None | None | None | MNZ, MNZ | Survived | This |
| 50       | 64        | M    | Peritonitis | Peritoneal fluid | D. piger | unknown | 16S rDNA | unknown | unknown | unknown | unknown | unknown | unknown | unknown | [14] |
| 51       | 83        | F    | Peritonitis | Peritoneal fluid | D. piger | unknown | 16S rDNA | unknown | unknown | unknown | unknown | unknown | unknown | unknown | [14] |
| 52       | 81        | F    | Rectal cancer | Peritoneal fluid | D. piger | unknown | 16S rDNA | unknown | unknown | unknown | unknown | unknown | unknown | unknown | [14] |
| 53       | 88        | F    | Peritonitis | Peritoneal fluid | D. piger | unknown | 16S rDNA | unknown | unknown | unknown | unknown | unknown | unknown | unknown | [14] |
| 54       | 84        | M    | Appendicitis | Abdominal collection | D. piger | unknown | 16S rDNA | unknown | unknown | unknown | unknown | unknown | unknown | unknown | [14] |
| 55       | 18        | M    | Peritonitis | Peritoneal fluid | D. piger | unknown | 16S rDNA | unknown | unknown | unknown | unknown | unknown | unknown | unknown | [14] |
| 56       | 9         | M    | Appendicitis, perforated appendix, abdominal abscess | Peritoneal fluid | D. piger | unknown | 16S rDNA | unknown | unknown | unknown | unknown | unknown | unknown | unknown | [14] |
| 57–58    | unknown   | unknown | unknown   | unknown | D. piger | unknown | 16S rDNA | unknown | unknown | unknown | unknown | unknown | unknown | unknown | [4] |
| 59       | 73        | F    | Bacteraemia, abdominal abscess | Blood | D. piger | E. coli, B. ovatus | 16S rDNA | 2 days | CLI, MNZ | unknown | unknown | unknown | unknown | [20] |
| 60       | 63        | M    | Perforated acute appendicitis | Peritoneal fluid | D. piger | unknown | 16S rDNA | unknown | unknown | unknown | unknown | unknown | unknown | unknown | Survived |
| 61       | unknown   | unknown | Abdominal abscess | Peritoneal fluid | D. vulgaris | None | unknown | unknown | unknown | unknown | unknown | unknown | unknown | unknown | [26] |
| 62–64    | unknown   | unknown | unknown   | unknown | D. vulgaris | Gram-positive cocci | Biochemical | 2 days | KAN | unknown | unknown | unknown | unknown | unknown | [4] |
| 65       | 15        | M    | Brain abscess | Pus | D. vulgaris | Gram-positive cocci | Biochemical | 2 days | KAN | unknown | unknown | unknown | unknown | unknown | [27] |
| 66       | 70        | F    | Left-shoulder prosthetic-joint infection | Synovial fluid, prosthetic joint | D. legallii | None | 16S rDNA | 10 days | CLI, MNZ, ETP, AMC, CRO | unknown | unknown | Survived | [20] |
Table 1 (continued)

| Case no. | Age (yrs) | Sex | Infection | Source | Genus/species | Co-isolated/co-infected organism(s) | Identification | Time for positive incubation | Antibiotic susceptibility (Susceptible) | Antibiotic therapy | Outcome | Ref. |
|----------|-----------|-----|-----------|--------|---------------|-----------------------------------|---------------|-----------------------------|------------------------------------------|------------------|---------|-----|
| 67       | unknown   | unknown | Acute appendicitis | Peritoneal fluid | Desulfovibrio sp. | unknown | Biochemical | unknown | unknown | unknown | unknown | [28] |
| 68       | unknown   | unknown | Perforating appendicitis | Peritoneal fluid | Desulfovibrio sp. | unknown | Biochemical | unknown | unknown | unknown | unknown | |
| 69       | 60 | M | Perforated acute appendicitis | Blood | Desulfovibrio sp. | E. lenta, anaerobic Gram-negative rod, B. fragilis | 16S rDNA | 3 days | CLI, MNZ | unknown | Survived | [20] |
| 70       | 74 | M | Septic shock, intra-abdominal infection | Blood | Desulfovibrio sp. | Candida parapsilosis | 16S rDNA | 5 days | unknown | unknown | Died | |
| 71       | 45 | M | Subphrenic abscess, abdominal infection | Blood | Desulfovibrio sp. | In subphrenic abscess: vancomycin-resistant enterococci | 16S rDNA | 5 days | unknown | unknown | Survived | |
| 72       | 93 | F | Sigmoid diverticulitis | Blood | Desulfovibrio sp. | None | 16S rDNA | 6 days | CLI, MNZ | unknown | Died | |

(*) Although a human infection of Desulfovibrio species (specifically D. desulfuricans, presented as bacteraemia associated with cholecystitis) was first reported in 1987, the strain was considered as D. faerlichii in 2005 Ref [28] Reference, M male, F female, MALDI-TOF MS Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry, B Bacteroides, D Desulfovibrio, E. coli Escherichia coli, E. lenta Eggerthella lenta, E. lentum Eubacterium lentum, K Klebsiella, ACV acyclovir, AMC amoxicillin-clavulanic acid, AMK amikacin, AMP ampicillin, AMX amoxicillin, AZM azithromycin, BIPM biapenem, CAZ ceftazidime, CTZ ceftriaxone, DOR doripenem, EMB ethambutol, ERY erythromycin, ETP ertapenem, FAM cefamandole, FEP cefepime, FOF fosfomycin, GAT gatifloxacin, INH isoniazid, IPM imipenem, KAN kanamycin, LVX levofloxacin, MEM meropenem, MNZ metronidazole, MXF moxifloxacin, ONZ ornidazole, PAPM panipenem, PEF pefloxacin, PEN penicillin, PIP piperacillin, RIF rifampin, SAM ampicillin-sulbactam, SBT/CFZ Cefoperazone sodium and sulbactam sodium, SBTCP sulbactam, TET tetracycline, TIM ticarcillin-clavulanic acid, TZP piperacillin-tazobactam, VAN vancomycin
organism identification is expected to increase because it is a novel method that can rapidly identify bacteria and be as accurate as 16S rDNA. In addition, 72% of the cases were identified after 3 days in cultures, and 24% were identified after 7 days (Table 2). Therefore, if the causative bacteria are unknown, performing the culture for a longer period is necessary.

In this case, contrast-enhanced CT and plain MRI identified the infected renal cyst, but 18-fluorodeoxyglucose positron emission tomography/CT (18FDG PET/CT) has been reported to be useful in the diagnosis of renal cyst infection [35, 36]. However, this method is not commonly used in Japan due to cost, where the national health insurance system allows the use of 18FDG PET/CT for malignant tumours mainly.

The routes of renal cyst infection include hematogenous routes and retrograde infection from the urinary tract. In the literature review, bloodstream infection was the most common among Desulfovibrio infection, followed by intra-abdominal infection, while urinary tract infection was less common at 3.6% (Table 2). He was in regular contact with soil and sewage, which are dwelling sites of the bacteria, due to his occupation. Since most of the Desulfovibrio species are also found in the environment, and since haemodialysis patients have reduced urine volume and are unable to cleanse themselves through urination, we suspected that the bacteria had entered the urinary tract and caused the infection retrogradely. However, it has been reported that D. fairfieldensis survives only in the human intestinal tract [4, 25], and we thought that it was more likely that the infection was haematogenous.

Infected cysts need early percutaneous cyst drainage, which provides the best treatment results because antibiotics alone do not usually treat the infection [33, 37]. In this case, the patient’s condition improved after drainage was performed.

For antimicrobial treatment of renal cyst infections, lipid-permeable antimicrobials with high penetration are recommended as first-line agents [32, 37]. Therefore, we also used ciprofloxacin as a quinolone, but with poor improvement. Then, we used meropenem which has been reported to have clinical improvement for cyst infection despite the poor penetration [8], but there was no improvement. The other antimicrobial agents for this patient were used as empirical treatments.

Optimal antimicrobial therapy for D. fairfieldensis remains controversial. One study showed that metronidazole had the highest antibacterial activity, while imipenem was effective against it [1]. Another study showed that imipenem, ciprofloxacin, clindamycin, chloramphenicol, and beta-lactams, except carbapenems, were ineffective [2]. Lipid-permeable antimicrobials such as metronidazole and clindamycin increase the concentrations of the antimicrobials in the renal cyst fluid [38]. Therefore, oral metronidazole was used for this patient. In addition, D. fairfieldensis may be more resistant to antimicrobial agents and have higher pathogenicity than other Desulfovibrio species [1–3]. Metronidazole

### Table 2
Summary of clinical characteristics of cases of infection with Desulfovibrio species in 27 articles

| Characteristics of cases |   |
|--------------------------|---|
| Total number of cases    | 72  |
| Median age (years)       | 65  |
| Female, male (%)         | 19,32 (37, 63) |
| Infection (%)            |   |
| Abscess                  | 15 (28) |
| Abdominal abscess        | 8 (15) |
| Liver abscess            | 2 (3.6) |
| Bacteraemia              | 14 (26) |
| Appendicitis             | 11 (20) |
| Central nervous system infection | 4 (7.4) |
| Source (%)               |   |
| Blood                    | 26 (47) |
| Peritoneal fluid         | 14 (26) |
| Pus                      | 9 (16) |
| Urine                    | 2 (3.6) |
| Total genus/species (%)  | 73  |
| D. fairfieldensis        | 26 (36) |
| D. desulfuricans         | 24 (33) |
| D. piger                 | 11 (15) |
| D. vulgaris              | 5 (6.8) |
| D. legallii              | 1 (1.4) |
| Co-isolate (%)           | 22 (54) |
| E. coli                  | 9 (22) |
| E. lenta (E. lentum)     | 7 (17) |
| K. pneumoniae            | 3 (7.4) |
| None                     | 19 (46) |
| Identification (%)       |   |
| 16S rDNA                 | 47 (87) |
| MALDI-TOF MS             | 3 (5.6) |
| Biochemical              | 7 (13) |
| Time for positive incubation (%) |   |
| 2 days                   | 2 (6.9) |
| 3 days                   | 6 (21) |
| > 3 days                 | 21 (72) |
| > 7 days                 | 7 (24) |
| Median (days)            | 5   |
| Outcome (%)              |   |
| Survived                 | 34 (89) |
| Died                     | 4 (11) |

Percentages for each category are calculated excluding “unknown”. D Desulfovibrio, E. coli Escherichia coli, E. lenta Eggerthella lenta, E. lentum Eubacterium lentum, K Klebsiella, MALDI-TOF MS Matrix-assisted laser desorption ionization time-of-flight mass spectrometry
was effective with good blood levels in the renal cysts of patients with ADPKD, including those on haemodialysis [38]. Summarising the previous reports of *Desulfovibrio* species infection, metronidazole showed the highest susceptibility (78%), and clindamycin was also effective (Table 3). However, metronidazole was used in only 23% of the patients; given that *D. fairfieldensis* is more resistant to antimicrobial agents and more pathogenic than other *Desulfovibrio* species [1–4], identifying the *Desulfovibrio* species, especially in *D. fairfieldensis*, by PCR tests, and using metronidazole, are essential for patient prognosis. In addition, because 54% of the patients with *Desulfovibrio* infection were complicated with other bacteria, there is concern that *Desulfovibrio* species can manifest when antimicrobial agents which are susceptible to other bacteria but resistant to *Desulfovibrio* are used (Table 2). The prognosis of *Desulfovibrio* infection was 11% of death, and treatment should be carefully selected, including appropriate drainage and antimicrobial agents.

The essential recommendations for the general treatment of renal cyst infection, including *Desulfovibrio* species, are as follows: if the bacteria of renal cyst infection are unknown, focus on long-term culture studies, consider identification of the organism by 16S rDNA or MALDI-TOF MS, consider the possibility of multiple bacterial complications. Some bacteria have a high mortality rate, and drainage should be performed first if possible and appropriate antimicrobials should be administered according to the organism.

To conclude, this is the first report of a renal cyst infection with the genus *Desulfovibrio* species to the best of our knowledge. *D. fairfieldensis* has higher pathogenicity and more antimicrobial resistance than other *Desulfovibrio* species and is difficult to detect. PCR tests can detect this bacterium and ensure better management for a successful recovery.

### Table 3 Summary of antimicrobial susceptibility of *Desulfovibrio* species and actual antibiotic therapy

| Antimicrobial susceptibility (%) | Antimicrobial therapy (%) |
|---------------------------------|---------------------------|
| **MNZ** 25 (78)                 | 5 (23)                    |
| **CLI** 21 (66)                 | 1 (4.5)                   |
| **IPM** 10 (31)                 | 1 (4.5)                   |
| **AMC** 9 (28)                  | 3 (14)                    |
| **ETP** 4 (13)                  | 0                         |
| **PEN** 3 (9.4)                 | 0                         |
| **SAM** 3 (9.4)                 | 2 (9.1)                   |
| **MEM** 3 (9.4)                 | 2 (9.1)                   |
| **LVX** 3 (9.4)                 | 0                         |
| **CIP** 3 (9.4)                 | 3 (14)                    |
| **TJP** 2 (6.3)                 | 4 (18)                    |
| **PAPM** 1 (3.1)                | 0                         |
| **AMP** 1 (3.1)                 | 2 (9.1)                   |
| **CRO** 1 (3.1)                 | 1 (3.1)                   |

AMC amoxicillin-clavulanic acid, AMP ampicillin, CIP ciprofloxacin, CLI clindamycin, CRO ceftriaxone, ETP ertapenem, IPM imipenem, LVX levofloxacin, MEM meropenem, MNZ metronidazole, PAPM panipenem, PEN penicillin, SAM ampicillin-sulbactam, TJP piperacillin-tazobactam

### Abbreviations

ADPKD: Autosomal dominant polycystic kidney disease; CRP: C-reactive protein; CT: Computed tomography; MRI: Magnetic resonance imaging; PCR: Polymerase chain reaction; 18FDG PET/CT: 18-fluorodeoxyglucose positron emission tomography/computed tomography; MALDI-TOF MS: Matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

### Acknowledgements

We are deeply grateful to the nursing and medical team of the Department of Nephrology, Tokyo Women's Medical University Hospital. We thank Editage (www.editage.jp) for English language editing.

### Funding

No funding was received for this work.

### Availability of data and materials

All data generated or analysed during this study are included in the published article.

### Declarations

**Ethical approval and consent to participate**

Informed consent was obtained from the patient for the publication of this case report and accompanying images.

**Consent for publication**

The patient in this case report provided written informed consent for his information and images to be published.

**Competing interests**

The authors declare no competing interests.

### Author details

1. Department of Nephrology, Tokyo Women’s Medical University, 8-1 Kawada-Cho, Shinjuku-ku, Tokyo 1628666, Japan. 2. Department of Infectious Diseases, Tokyo Women’s Medical University, 8-1 Kawada-Cho, Shinjuku-ku, Tokyo 1628666, Japan.

### Received: 24 February 2022 Accepted: 25 April 2022

Published online: 23 May 2022

**References**

1. Goldstein EJC, Citron DM, Peraino VA, Cross SA. Desulfovibrio desulfuricans bacteremia and review of human Desulfovibrio infections. J Clin Microbiol. 2003;41:2752–4.

2. Pimentel JD, Chan RC. Desulfovibrio fairfieldensis bacteremia associated with choledocholithiasis and endoscopic retrograde cholangiopancreatography. J Clin Microbiol. 2007;45:2747–50.

3. Loubinoux J, Mory F, Pereira IAC, Faou AEL. Bacteremia caused by a strain of Desulfovibrio related to the provisionally named Desulfovibrio fairfieldensis. J Clin Microbiol. 2000;38:931–4.
4. Warren YA, Citron DM, Merriam CV, Goldstein EJC. Biochemical differentiation and comparison of Desulfovibrio species and other phenotypically similar genera. J Clin Microbiol. 2005;43:4041–5.

5. Scola BL, Raoult D. Third human isolate of a Desulfovibrio sp. identical to the provisionally named Desulfovibrio faerderi. J Clin Microbiol. 1999;37:3076–7.

6. Tee W, Dyall-Smith M, Woods W, Eisen D. Probable new species of Desulfovibrio isolated from a pyogenic liver abscess. J Clin Microbiol. 1996;34:1760–4.

7. Urata T, Kikuchi M, Hino T, Yoda Y, Tamai K, Kodaia Y, et al. Bacteremia caused by Desulfovibrio faerderi. J Infect Chemother. 2008;14:368–70.

8. Hamanoue S, Suwabe T, Ubara Y, Kikuchi K, Hazue R, Mise K, et al. Cyst infection in autosomal dominant polycystic kidney disease: penetration of merozoites into infected cysts. BMC Nephrol. 2018;19:272.

9. Hone S. New strategy for the treatment of autosomal dominant polycystic kidney disease. Nihon Jinzo Gakkai Shi. 2015;57:524–61.

10. Hagiya H, Kimura K, Nishi I, Yamamoto N, Yoshida H, Akeda Y, et al. Desulfovibrio desulfuricans bacteremia: a case report and literature review. Anaerobe. 2018;49:112–5.

11. Porschen RK, Chan P. Anaerobic virbio-like organisms cultured from blood: Desulfovibrio desulfuricans and Succinivibrio species. J Clin Microbiol. 1977;5:444–7.

12. McDougall R, Robson J, Paterson D, Tee W. Bacteremia caused by a recently described novel Desulfovibrio species. J Clin Microbiol. 1997;35:1805–8.

13. Liderot K, Larsson M, Boräng S, Özenci V. Polyomicrobial bloodstream infection with Eggerthella lenta and Desulfovibrio desulfuricans. J Clin Microbiol. 2003;41:1304–6.

14. Lantinga MA, Castelein NF, Geudens A, de Sévaux RGL, van Assen S, Lellieveld AM, et al. Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review. Nephrol Dial Transplant. 2017;32:144–50.

15. Loubinoux J, Jaulhac B, Piemont Y, Monteil H, Faou AEL. Isolation of a recently described novel Desulfovibrio species. J Clin Microbiol. 2003;41:1304-6.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.